[Skip to Content]
[Skip to Content Landing]
Article
January 1940

TREATMENT OF MULTIPLE SCLEROSIS WITH NICOTINIC ACID AND VITAMIN B1: PRELIMINARY REPORT

Author Affiliations

PHILADELPHIA

From the Jewish Hospital and the John L. Eckel Neuropathological Laboratory, University of Pennsylvania Graduate School of Medicine.

Arch Intern Med (Chic). 1940;65(1):1-20. doi:10.1001/archinte.1940.00190070011001
Abstract

The treatment of advanced multiple sclerosis with nicotinic acid and a combination of nicotinic acid and thiamin chloride has yielded promising results in cases in which the patients have failed to respond to therapies hitherto used. While complete remission has not been obtained, the use of the treatment suggested here has resulted in continued symptomatic improvement. The potential value of the suggested treatment may be judged in the light of prevailing conceptions of the etiology and treatment of multiple sclerosis.

From 1838, when Sir Robert Carswell, as cited by Putnam,1 first described the pathology of multiple sclerosis, up to the present, the treatment of this disease has been entirely empiric. When one examines the diversity of remedial agents and methods employed, it becomes evident that the disarray is occasioned by complete ignorance of the etiology of the disease, coupled with the desire to find a remedy for one of the

References
1.
Putnam, T. J.:  The Centenary of Multiple Sclerosis ,  Arch. Neurol. & Psychiat. 40:806 ( (Oct.) ) 1938.
2.
Brain, W. R.:  Critical Review: Disseminated Sclerosis ,  Quart. J. Med. 23:343 ( (April) ) 1930.
3.
 Problems of Disseminated Sclerosis , editorial,  J. Neurol. & Psychopath. 13:227 ( (Jan.) ) 1933.
4.
Hassin, G.:  The Pathogenesis of Multiple Sclerosis ,  Arch. Neurol. & Psychiat. 7:589 ( (May) ) 1922.
5.
Brickner, R. M.:  Studies on the Pathogenesis of Multiple Sclerosis ,  Arch. Neurol. & Psychiat. 23:715 ( (April) ) 1930.
6.
Jelliffe, S. E., and White, W. A.:  Diseases of the Nervous System , Philadelphia, Lea & Febiger, 1923, p. 562.
7.
Steiner, G.:  Multiple Sclerosis: The Etiological Significance of the Regional and Occupational Incidence ,  J. Nerv. & Ment. Dis. 88:42 ( (July) ) 1938.
8.
Bullock, W. E.:  The Experimental Transmission of Disseminated Sclerosis ,  Lancet 2:1185, 1913.
9.
Steiner, G.:  Multiple Sklerose ,  Therap. Halbmonatsh. 34:68 ( (Feb. 1) ) 1920.
10.
Schuster, G.:  Spirochetes in the Etiology of Certain Paralyses ,  Lancet 1:21 ( (Jan. 1) ) 1921.
11.
Chevassut, K.:  Aetiology of Disseminated Sclerosis ,  Lancet 1:552 ( (March 15) ) 1930.
12.
Purves-Stewart, J.:  A Specific Vaccine Treatment in Disseminated Sclerosis ,  Lancet 1:560 ( (March 15) ) 1930.
13.
Putnam, T. J.:  The Pathogenesis of Multiple Sclerosis: A Possible Vascular Factor ,  New England J. Med. 209:876 ( (Oct. 19) ) 1933
14.
 Evidences of Vascular Occlusion in Multiple Sclerosis and "Encephalomyelitis,"  Arch. Neurol. & Psychiat. 37:1298 ( (June) ) 1937.
15.
Zimmerman, H. M., and Burack, E.:  Lesions of the Nervous System Resulting from a Deficiency of the Vitamin B Complex ,  Arch. Path. 13:207 ( (Feb.) ) 1932.
16.
Gowers, W. R.:  A Manual of Diseases of the Nervous System , Philadelphia, P. Blakiston, Son & Co., 1888, p. 930.
17.
Oppenheim, H.:  Text-Book of Nervous Diseases , translated by A. Bruce, ed. 5, Edinburgh, Otto Schulze & Co., 1911, vol. 1, pp. 33 and 350.
18.
Credé's ointment contains 15 per cent of collargol (a proprietary preparation of colloidal silver and silver nitrate, stabilized by egg albumin), 5 per cent of water, 10 per cent of white wax and 70 per cent of benzoinated lard.
19.
Brickner, R. M.:  A Critique of Therapy in Multiple Sclerosis ,  Bull. Neurol. Inst. New York 4:665 ( (April) ) 1936.
20.
Bennett, A. E.:  Evaluation of Artificial Fever Therapy for Neuropsychiatric Disorders ,  Arch. Neurol. & Psychiat. 40:1141 ( (Dec.) ) 1938.
21.
Collins, R. T.:  Transitory Neurological Changes During Hyperthermia ,  Bull. Neurol. Inst. New York 7:291 ( (Dec.) ) 1938.
22.
Smith, D. T.; Ruffin, J. M., and Smith, S. G.:  Pellagra Successfully Treated with Nicotinic Acid: A Case Report ,  J. A. M. A. 109:2054 ( (Dec. 18) ) 1937.
23.
Stephenson, J.:  Diathermy in Multiple Sclerosis: Report of Progress ,  Physical Therap. 46:373 ( (Aug.) ) 1928.
24.
Dreyfus, G. L., and Mayer, K.:  Vier Jahre Malariabehandlung der multiplen Sklerose ,  Deutsche Ztschr. f. Nervenh. 111:68, 1929.
25.
Schmidt, W. H., and Weiss, B. P.:  Fever Produced by Diathermy: Its Value in Multiple Sclerosis and Other Chronic Diseases ,  Physical Therap. 49: 336 ( (Sept.) ) 1931.
26.
Neymann, C. A., and Osborne, S. L.:  The Treatment of Some Multiple Sclerotics by Electropyrexia ,  J. Nerv. & Ment. Dis. 79:423 ( (April) ) 1934.
27.
Weiss, B. P.:  Further Observations on the Treatment of Multiple Sclerosis by Hyperpyrexia ,  M. Rec. 142:489 ( (Dec. 4) ) 1935.
28.
Wetherell, F.:  Multiple Sclerosis: Cervicodorsal Sympathectomy as a Relief Measure; Report of a Case ,  J. A. M. A. 102:1754 ( (May 26) ) 1934.
29.
Royle, N. D.:  The Surgical Treatment of Disseminated Sclerosis ,  M. J. Australia 1:586 ( (May 13) ) 1933.
30.
Koch, C. F., and de Savitsch, E.:  Surgical Treatment of Disseminated Sclerosis by Sympathectomy and Ganglionectomy: Technique by the Anterior Approach ,  Brit. M. J. 1:1254 ( (June 11) ) 1938.
31.
Hartman, F. W.:  Lesions of the Brain Following Fever Therapy: Etiology and Pathogenesis ,  J. A. M. A. 109:2116 ( (Dec. 25) ) 1937.
32.
Bennett.12a
33.
Collins.12b
34.
Spies, T. D.; Cooper, C., and Blankenhorn, M. A.:  The Use of Nicotinic Acid in the Treatment of Pellagra ,  J. A. M. A. 110:622 ( (Feb. 26) ) 1938.
35.
Spies, T. D.; Bean, W. B., and Stone, R. E.:  The Treatment of Subclinical and Classic Pellagra: Use of Nicotinic Acid, Nicotinic Acid Amide and Sodium Nicotinate, with Special Reference to the Vasodilator Action and the Effect on Mental Symptoms ,  J. A. M. A. 111:584 ( (Aug. 13) ) 1938.
36.
Elsberg, C. A., and Hare, C. C.:  A New and Simplified Manometric Test for the Determination of Spinal Subarachnoid Block by Means of the Inhalation of Nitrite of Amyl ,  Bull. Neurol. Inst. New York 2:347 ( (Nov.) ) 1932.
37.
Sollmann, T.:  A Manual of Pharmacology , Philadelphia, W. B. Saunders Company, 1936, pp. 479-481.
38.
Hopkins, F. G.:  Biological Thought and Chemical Thought ,  Lancet 1:1201 ( (May 28) ) 1938.
39.
Matthews, R. S.:  Pellagra and Nicotinic Acid ,  J. A. M. A. 111:1148 ( (Sept. 24) ) 1938.
40.
Spies, Bean and Stone.23b
41.
Spies, T. D., and Aring, C. D.:  The Effect of Vitamin Bi on the Peripheral Neuritis of Pellagra ,  J. A. M. A. 110:1081 ( (April 2) ) 1938.
42.
Lewy, F. H.:  Vitamin B Deficiency and Nervous Diseases ,  J. Nerv. & Ment. Dis. 89:1 ( (Jan.) ) 1939.
43.
Williams, R. R., and Spies, T. B.:  Vitamin B, (Thiamin) and Its Use in Medicine , New York, The Macmillan Company, 1938, p. 131.
44.
Lipschitz, M. A.; Potter, V. R., and Elvehjem, C. A.:  The Metabolism of Pyruvic Acid in Vitamin Bi Deficiency and in Inanition ,  J. Biol. Chem. 123: 267 ( (March) ) 1938.
45.
Hopkins.26
46.
Stern, E. L.:  The Intraspinal (Subarachnoid) Injection of Vitamin Bi for the Relief of Intractable Pain, and for Inflammatory and Degenerative Diseases of the Central Nervous System ,  Am. J. Surg. 34:495 ( (March) ) 1938.
×